Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

edically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... DC (PRWEB) August 21, 2014 Atlantic ... publisher of ACO Business News and The AIS Report ... with the Blue Cross Blue Shield Association or its ... of the latest report in AIS’s Management Insight Series. ... offers case studies of two insurers — Horizon Healthcare ...
(Date:8/21/2014)... Only 20 percent of healthcare providers currently meet ... according to a new report . , Over 200 ... request from Smart Data pioneer peer60. Participants reported ... violate privacy laws in many states. , “Reaching the ACA’s ... clinics are failing to do so in part because it ...
(Date:8/21/2014)... Consilium Staffing, Your Partner in Locum Tenens, ... in response to the President’s landmark VA hospital reform ... the Department of Veterans Affairs to hire more doctors. ... one hundred fifty medical centers nationwide, and has been ... awaiting treatment, including vets from the Vietnam War, Iraq, ...
(Date:8/21/2014)... 2014 Inc. magazine ranked Centurion Service ... an exclusive ranking of the nation's fastest-growing private companies. ... most important segment of the economy—America’s independent entrepreneurs. Companies ... Zillow, and many other well-known names gained early exposure ... proud to have been named to the Inc. 5000 ...
(Date:8/21/2014)... Centre, NY (PRWEB) August 21, 2014 ... law firm with over 25 years of experience advocating ... prescription drugs and defective medical devices, announces the launch ... information to those women who believe they have been ... site offers valuable information about the severe adverse side ...
Breaking Medicine News(10 mins):Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Consilium Staffing Providing Locum Tenens in Response to VA Hospital Reform Legislation 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2
... ANGELES, Nov. 25 The Black AIDS Institute recently held ... , The new Board Members are a highly diverse group ... health programs, editorial, and business entrepreneurship. The Board also comes ... and gay Black men and women, some living with HIV ...
... significant survival benefit from adjuvant tamoxifen among patients ... of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), ... 25 in the Journal of the National ... carcinomas are resistant to tamoxifen. Preclinical studies have ...
... fight rheumatoid arthritis, could help newly diagnosed diabetics, study ... drug commonly used to treat non-Hodgkin,s lymphoma and rheumatoid ... newly diagnosed with type 1 diabetes. , The drug, ... own insulin, even though the disease had destroyed some ...
... CDC sees few signs of trouble with the H1N1 ... ongoing H1N1 swine flu pandemic may be driving a ... U.S. health official said Wednesday. , "We are seeing ... Dr. Anne Schuchat, director of the National Center for ...
... the body on a carefully engineered, fingernail-sized implant is ... report this week in the journal Science Translational ... and immunologists at Harvard University, uses plastic disks impregnated ... reprogram the mammalian immune system to attack tumors. The ...
... parts of speech colored perception of sounds , WEDNESDAY, Nov. ... their ears, but also with their skin, new research shows. ... certain types of speech actually helped people decipher sounds better, ... to show whether we could use tactile information in this ...
Cached Medicine News:Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
Inquire...
... design makes positioning quick and ... wheelchair accessible and can support ... lbs. The AIT-8B provides stable ... units and includes a motorized ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... FDA-Approved BV-1000 is the worlds ... system. With the BV-1000, Topcon ... of refracting instruments. This innovative ... binocular auto-refractor, auto-keratometer, automatic chart ...
Medicine Products: